Pulmatrix, Inc. — Q1 2024 Form 10-Q
Business context and reporting period. Pulmatrix is a clinical-stage biopharmaceutical company developing inhaled therapeutics using its iSPERSE dry-powder delivery platform. This unaudited filing covers the three months ended March 31, 2024; financial statement amounts below are in thousands of dollars unless noted. Pulmatrix has no product sales; quarterly revenue was primarily from its PUR1900 collaboration with Cipla.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $5,885 | $1,499; up $4,386 (about 293%) |
| Research and development expense | $3,512 | $3,874; down $362 |
| General and administrative expense | $1,626 | $2,210; down $584 |
| Total operating expenses | $5,138 | $6,084; down $946 |
| Operating income (loss) | $747 | $(4,585) |
| Operating margin | About 12.7% | Not meaningful given operating loss |
| Net income (loss) | $825; $0.23 per share | $(4,448); $(1.22) per share |
| Cash used in operating activities | $(2,719) | $(4,928) |
The revenue increase and return to profitability principally reflect a $4.0 million cumulative catch-up revenue adjustment tied to the January 2024 Cipla contract amendment. That amount had been in deferred revenue at the start of the quarter; it is not evidence of product sales. The filing does not report a gross margin.
At March 31, 2024, cash and cash equivalents were $16,300, with an additional $1,472 of long-term restricted cash. Current assets were $17,582 and current liabilities $3,144. Total liabilities were $11,373, including $8,612 of operating lease liabilities; the filing reports no borrowing debt balance. Cash, cash equivalents and restricted cash declined $2,873 during the quarter. Investing used $154, primarily for equipment, and there was no financing cash flow.
Material changes, outlook and risks
- Operating expenses fell year over year: R&D costs declined mainly from lower PUR3100 spending and employment costs; G&A fell mainly from lower legal/professional and employment costs.
- Under the Cipla amendment, Pulmatrix and Cipla stopped enrollment in the PUR1900 Phase 2b study. Pulmatrix was to complete wind-down and technology-transfer activities by July 30, 2024, with the company stating it expected completion in Q3 2024. After the wind-down, Cipla bears development and commercialization costs outside the United States, and Pulmatrix is entitled to 2% royalties on potential future net sales there. The parties will seek to monetize PUR1900 in the United States.
- Pulmatrix said its March 31 cash was expected to fund operating expenses and capital requirements for at least 12 months following the filing, into Q1 2026. It nevertheless expects continuing losses and says additional capital will be needed for planned development and regulatory activities. It was exploring financing or partnership arrangements to initiate a potential PUR3100 Phase 2 study; the study was contingent on financing or partnership.
- Management expects substantial expenses and operating losses for at least the next several years. The Q1 profit is driven largely by the non-cash Cipla revenue catch-up, while operating cash flow remained negative.
- Key risks include dependence on additional financing, clinical and regulatory uncertainty, reliance on collaborators, and customer concentration: one customer represented 96% of Q1 revenue, and two customers represented 97% of accounts receivable at quarter-end. Cash was substantially held at one financial institution, creating exposure above insured limits.
- The company reported no material pending legal proceedings and no material noncancellable R&D commitments expected to be unreimbursed under the Cipla agreement. Disclosure controls were reported effective; no material internal-control changes were reported.
Pipeline context: PUR3100, an inhaled DHE candidate for acute migraine, is Phase 2-ready following FDA IND acceptance, but a Phase 2 start depends on financing or a partner. PUR1800 is being advanced through partnership or other alternatives. The filing also describes substantial remaining PUR3100 clinical and long-term safety requirements, including FDA-requested studies and patient exposure.
Important facts for investors to verify
- Whether Pulmatrix secures financing or a partner for PUR3100 and how that affects its cash runway and development plans.
- Completion and financial consequences of the PUR1900 wind-down, including the status of U.S. monetization efforts and any future Cipla royalties.
- How much of reported revenue and earnings reflects contract accounting catch-up rather than recurring collaboration activity; only $363 of deferred revenue was current at March 31, with no long-term deferred revenue reported.
- Cash burn, restricted-cash availability, and the ongoing lease obligation, including $8,612 of recorded lease liabilities.
- Potential dilution and capital-raising capacity: 3,652,285 common shares were outstanding at May 6, 2024; the company reported 1,153,702 warrants and 344,306 options outstanding at March 31. No ATM shares were sold in Q1, and Form S-3 limits may constrain ATM proceeds.